1. Home
  2. HROW vs OMCL Comparison

HROW vs OMCL Comparison

Compare HROW & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$31.15

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

HOLD

Current Price

$44.60

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HROW
OMCL
Founded
1998
1992
Country
United States
United States
Employees
373
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Manufacturing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
HROW
OMCL
Price
$31.15
$44.60
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$69.86
$55.83
AVG Volume (30 Days)
842.7K
589.8K
Earning Date
05-11-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
N/A
$787,309,000.00
Revenue This Year
$31.62
$6.77
Revenue Next Year
$50.77
$5.22
P/E Ratio
N/A
$175.16
Revenue Growth
N/A
9.93
52 Week Low
$25.21
$26.85
52 Week High
$54.98
$51.84

Technical Indicators

Market Signals
Indicator
HROW
OMCL
Relative Strength Index (RSI) 32.55 63.92
Support Level $29.15 $44.17
Resistance Level $41.67 $45.17
Average True Range (ATR) 1.87 1.51
MACD -0.85 -0.09
Stochastic Oscillator 18.64 86.34

Price Performance

Historical Comparison
HROW
OMCL

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Share on Social Networks: